First Time Loading...

Novo Nordisk A/S
NYSE:NVO

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
NYSE:NVO
Watchlist
Price: 122.75 USD -1.43% Market Closed
Updated: Apr 19, 2024
Section:
 

Relative Value

The Relative Value of one NVO stock under the Base Case scenario is 84.87 USD. Compared to the current market price of 122.75 USD, Novo Nordisk A/S is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NVO Relative Value
Base Case
84.87 USD
Overvaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

16.6
P/S
P/S
Price to Sales
16.6
vs History
1
vs Industry
11
Median 3Y
10.3
Median 5Y
8.8
Industry
2.4
Forward
13.2
More Details
46
P/E
P/E
Price to Earnings
46
vs History
1
vs Industry
8
Median 3Y
32
Median 5Y
26.8
Industry
22.2
Forward
36.5
More Details
35.3
P/OCF
P/OCF
Price to OCF
35.3
vs History
1
vs Industry
12
Median 3Y
23.5
Median 5Y
21.5
Industry
16.9
More Details
56.4
P/FCFE
P/FCFE
Price to FCFE
56.4
vs History
1
vs Industry
10
Median 3Y
27.5
Median 5Y
22.6
Industry
22.4
More Details
36.1
P/B
P/B
Price to Book Value
36.1
vs History
1
vs Industry
1
Median 3Y
21.9
Median 5Y
18.1
Industry
2.1
More Details
16.5
EV/S
EV/S
Enterprise Value to Sales
16.5
vs History
1
vs Industry
9
Median 3Y
10.3
Median 5Y
8.7
Industry
2.6
Forward
13.2
More Details
19.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
19.5
vs History
1
vs Industry
10
Median 3Y
12.2
Median 5Y
10.4
Industry
5.1
More Details
33.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
33.6
vs History
1
vs Industry
9
Median 3Y
21.8
Median 5Y
18.6
Industry
13.6
Forward
27.6
More Details
36.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
36.6
vs History
1
vs Industry
11
Median 3Y
24.1
Median 5Y
20.5
Industry
16.9
Forward
29.6
More Details
35.2
EV/OCF
EV/OCF
Enterprise Value to OCF
35.2
vs History
1
vs Industry
12
Median 3Y
23.5
Median 5Y
21.3
Industry
15.8
More Details
54.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
54.8
vs History
1
vs Industry
9
Median 3Y
30.2
Median 5Y
26.8
Industry
17.6
More Details
14.8
EV/IC
EV/IC
Enterprise Value to IC
14.8
vs History
1
vs Industry
8
Median 3Y
9.3
Median 5Y
7.9
Industry
1.9
More Details

Multiples Across Competitors

NVO Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
NYSE:NVO
3.8T USD 16.6 46 33.6 36.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
708.2B USD 20.8 135.1 61 70.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
350.8B USD 4.1 10 11.2 14.7
US
Merck & Co Inc
NYSE:MRK
317B USD 5.3 868.6 43.3 84.5
UK
AstraZeneca PLC
LSE:AZN
169.2B GBP 4.6 35.3 139 223
CH
Roche Holding AG
SIX:ROG
175.4B CHF 3 15.3 8.4 10
CH
Novartis AG
SIX:NOVN
172.8B CHF 4.1 12.8 9.3 15.4
US
Pfizer Inc
NYSE:PFE
143.4B USD 2.5 67.7 10.4 15.5
FR
Sanofi SA
PAR:SAN
106.9B EUR 2.3 19.8 7.5 11
P/E Multiple
Earnings Growth
DK
Novo Nordisk A/S
NYSE:NVO
Average P/E: 134.5
46
84%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
135.1
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
10
-21%
US
Merck & Co Inc
NYSE:MRK
868.6
7 453%
UK
AstraZeneca PLC
LSE:AZN
35.3
168%
CH
Roche Holding AG
SIX:ROG
15.3
26%
CH
Novartis AG
SIX:NOVN
12.8
15%
US
Pfizer Inc
NYSE:PFE
67.7
678%
FR
Sanofi SA
PAR:SAN
19.8
120%

See Also

Summary
NVO intrinsic value, competitors valuation, and company profile.
DCF Valuation
NVO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NVO stock valuation using valuation multiples.
Wall Street Estimates
NVO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NVO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 129,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.